371 related articles for article (PubMed ID: 29959582)
1. Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Johnson SB; Yu JB
Curr Oncol Rep; 2018 Jun; 20(9):66. PubMed ID: 29959582
[TBL] [Abstract][Full Text] [Related]
2. Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.
Lee CY; Yang KL; Ko HL; Huang RY; Tsai PP; Chen MT; Lin YC; Hwang TI; Juang GD; Chi KH
Radiat Oncol; 2014 Sep; 9():213. PubMed ID: 25248470
[TBL] [Abstract][Full Text] [Related]
3. Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions.
Jiang DM; Chung P; Kulkarni GS; Sridhar SS
Curr Oncol Rep; 2020 Feb; 22(2):14. PubMed ID: 32008105
[TBL] [Abstract][Full Text] [Related]
4. Trimodality therapy for bladder conservation in treatment of invasive bladder cancer.
Mitin T; Shipley WU; Efstathiou JA; Heney NM; Kaufman DS; Lee RJ; Zietman AL
Curr Urol Rep; 2013 Apr; 14(2):109-15. PubMed ID: 23341373
[TBL] [Abstract][Full Text] [Related]
5. Selective organ preservation in muscle-invasive bladder cancer: review of the literature.
Khosravi-Shahi P; Cabezón-Gutiérrez L
Surg Oncol; 2012 Mar; 21(1):e17-22. PubMed ID: 22088598
[TBL] [Abstract][Full Text] [Related]
6. Trimodality therapy in bladder cancer: who, what, and when?
Premo C; Apolo AB; Agarwal PK; Citrin DE
Urol Clin North Am; 2015 May; 42(2):169-80, vii. PubMed ID: 25882559
[TBL] [Abstract][Full Text] [Related]
7. Contemporary and Emerging Approaches to Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Konieczkowski DJ; Efstathiou JA; Mouw KW
Hematol Oncol Clin North Am; 2021 Jun; 35(3):567-584. PubMed ID: 33958151
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer.
Royce TJ; Feldman AS; Mossanen M; Yang JC; Shipley WU; Pandharipande PV; Efstathiou JA
Clin Genitourin Cancer; 2019 Feb; 17(1):23-31.e3. PubMed ID: 30482661
[TBL] [Abstract][Full Text] [Related]
9. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
Arcangeli G; Strigari L; Arcangeli S
Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
[TBL] [Abstract][Full Text] [Related]
10. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer.
Coen JJ; Paly JJ; Niemierko A; Kaufman DS; Heney NM; Spiegel DY; Efstathiou JA; Zietman AL; Shipley WU
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):311-6. PubMed ID: 23474117
[TBL] [Abstract][Full Text] [Related]
11. Bladder-sparing treatment options in localized muscle-invasive bladder cancer.
Nason GJ; Ajib K; Tan GH; Kulkarni GS
Expert Rev Anticancer Ther; 2020 Mar; 20(3):179-188. PubMed ID: 32129122
[No Abstract] [Full Text] [Related]
12. Trimodality therapy for bladder cancer: modern management and future directions.
Pham A; Ballas LK
Curr Opin Urol; 2019 May; 29(3):210-215. PubMed ID: 30855374
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC).
Arcangeli G; Arcangeli S; Strigari L
Crit Rev Oncol Hematol; 2015 Apr; 94(1):105-15. PubMed ID: 25541350
[TBL] [Abstract][Full Text] [Related]
14. [Organ-sparing treatment of bladder cancer].
Niedworok C; Shaleva A; Rübben H; Stenzl A
Urologe A; 2016 May; 55(5):609-14. PubMed ID: 27119956
[TBL] [Abstract][Full Text] [Related]
15. Bladder cancer: bladder preservation--learning what we don't know.
Hussain M; Theodorescu D
Nat Rev Urol; 2014 Jun; 11(6):310-2. PubMed ID: 24841166
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
[TBL] [Abstract][Full Text] [Related]
17. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
[TBL] [Abstract][Full Text] [Related]
18. Can bladder preservation therapy come to the center stage?
Inamoto T; Ibuki N; Komura K; Juri H; Yamamoto K; Yamamoto K; Fujita K; Nonomura N; Narumi Y; Azuma H
Int J Urol; 2018 Feb; 25(2):134-140. PubMed ID: 29171098
[TBL] [Abstract][Full Text] [Related]
19. Trimodal therapy for muscle-invasive bladder cancer.
Mathes J; Rausch S; Todenhöfer T; Stenzl A
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1219-1229. PubMed ID: 30324833
[TBL] [Abstract][Full Text] [Related]
20. Bladder preservation in muscle-invasive bladder cancer: a comprehensive review.
Hamad J; McCloskey H; Milowsky MI; Royce T; Smith A
Int Braz J Urol; 2020; 46(2):169-184. PubMed ID: 31961624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
